This post is from a low-reputation account and contains an unverified outbound link. Be cautious before clicking external links.
The introduction of BTK inhibitors has transformed the treatment landscape for CLL, MCL, and WM, offering patients a more effective and tolerable alternative to traditional therapies. By specifically targeting cancer cells and minimising damage to healthy ones, these treatments have provided new hope for many battling blood cancers.